Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

• Status: RECRUITING
• Trial end date: 2029-02-01

Summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

• Phase: PHASE1

Details

• Lead Sponsor: ModeX Therapeutics, An OPKO Health Company